PARIS (Reuters) - Sanofi said on Friday its experimental pill for Gaucher disease met its main targets in two late-stage studies, which the French drugmaker will use to bolster its case for regulatory approval. If approved, eliglustat tartrate could become the first-oral treatment for Gaucher disease, a rare genetic disorder affecting some 10,000 patients worldwide. (Reporting by Elena Berton; Editing by Christian Plumb)